TG Therapeutics +8.3% Premarket @$15.00 on Light Trading; Said Phase 3 GENUINE Trial Met Primary Endpoint with TG-1101 + Ibrutinib Increasing Overall Response Rate by >70% vs Ibrutinib Alone
Charles Gross